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Pencil-beam scanning (PBS) proton therapy (PT), particularly intensity modulated PT, represents the latest advanced PT
technology for treating cancers, including thoracic malignancies. On the basis of virtual clinical studies, PBS-PT appears
to have great potential in its ability to tightly tailor the dose to the target while sparing critical structures, thereby
reducing treatment-related toxicities, particularly for tumors in areas with complicated anatomy. However, implementing
PBS-PT for moving targets has several additional technical challenges compared with intensity modulated photon radi-
ation therapy or passive scattering PT. Four-dimensional computed tomographyebased motion management and robustReprint requests to: Joe Y. Chang, MD, PhD, Department of Radiation
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Chang et al. International Journal of Radiation Oncology  Biology  Physics42optimization and evaluation are crucial for minimizing uncertainties associated with beam range and organ motion.
Rigorous quality assurance is required to validate dose delivery both before and during the course of treatment. Active
motion management (eg, breath hold), beam gating, rescanning, tracking, or adaptive planning may be needed for cases
involving significant motion or changes in motion or anatomy over the course of treatment.  2017 The Authors. Pub-
lished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Proton therapy (PT) for thoracic cancers can often sparemore
nearby critical structures than intensity modulated photon
radiation therapy (IMRT) (1-6). Passive scattering proton
therapy (PSPT) technology, however, relies on 3-dimensional
(3D) conformal treatment planning, with its inherent limita-
tions resulting from the lack of intensity modulation (7).
Tumors in complex anatomic positions and tumors that
curve around critical structures are extremely challenging
to treat with PSPT because of the inability of PSPT to
adjust its modulation width for the various thicknesses
throughout a target. This can lead to difficulty in mini-
mizing the mean lung dose, the lung volume received 20
Gy and above, and especially, the mean esophageal dose. In
such cases, dose coverage may be intentionally compro-
mised to avoid damaging critical normal tissue structures.
In contrast to PSPT, pencil-beam scanning (PBS) PT,
especially intensity modulated proton therapy (IMPT)done
of several pencil-beamdelivery optimization strategiesdcan
simultaneously optimize the intensities of pencil beams by
using an objective function that accounts for the shape and
density of targets, as well as constraints on normal
tissues. Dosimetric studies have demonstrated that PBS-PT,
especially IMPT, can reduce the dose to critical normal
tissues relative to IMRT and allow individualized radical
radiation therapy for clinically challenging cases of stage III
nonesmall cell lung cancer (NSCLC) (8-10). However, un-
certainties regarding the range of the proton beam going
through heterogeneous tissues, the interplay effect between
the motion of the scanning beam and respiratory motion, and
other aspects of treatment planning and quality assurance are
more challenging and complex for PBS-PT, especially IMPT,
than for PSPT or IMRT (11-15).
Preliminary results have shown that PBS-PT technology
can be safely implemented in the treatment of thoracic
cancers with minimal motion, and clinical outcomes seem
promising (16, 17). As additional proton centers, many
exclusively with PBS technology, are being built around the
world, the need for guidelines and consensus to address
these issues associated with PBS-PT is increasingly desir-
able. To meet this need, the Particle Therapy Co-Operative
Group (PTCOG) Thoracic and Lymphoma Subcommittee
developed this consensus guideline, on the basis of avail-
able physics and clinical findings, for the use of PBS-PT
including IMPT for thoracic tumors.Major Challenges of PBS-PT in Thoracic Cancers
Dosimetric impact of range uncertainty and
respiratory motion
In PT, unlike in photon therapy, the range uncertainty
resulting from the uncertainty in the Hounsfield units (HUs)
of computed tomography (CT) images and the values of
stopping powers must be accounted for. The range uncer-
tainty has the potential to alter the proton range and dose
distribution, which can result in underdosing the target
volume or overdosing critical structures. Additional un-
certainties from setup errors and intrafractional organ mo-
tion (primarily from respiration) not only cause geometric
displacement of tumors and normal tissues, blurring the
dose gradient from target volume to normal tissue, but also
can affect tissue densities, which can alter the ranges of
protons and influence dose distribution. An additional
source of uncertainty comes from interfractional organ
motion brought about by the opening of previously blocked
airways and anatomic changes (eg, the accumulation or
drainage of fluid), which can significantly change the pro-
ton range along the path of the proton beam.
The influence of these uncertainties becomes more sig-
nificant in IMPT or multifield-optimized (MFO) plans
(defined in Appendix E1; available online at www
.redjournal.org) because the individual fields can be highly
modulated and steep dose gradients can be located in the
middle of the target (18). Hence, the concept of a “safety
margin” is less effective for ensuring coverage with PBS-PT.
In addition, when PBS technology is used to treat
moving tumors, the interplay effect results in misplacement
of the individual pencil-beam spots relative to the planned
positions and can cause additional degradation of the
delivered dose distribution, potentially manifesting as
extreme local tumor underdosage or normal structure
overdosage (11, 12, 15, 19, 20). This effect is most pro-
nounced when PBS-PT is delivered in a limited number of
fractions such as in stereotactic ablative radiation therapy
(21), which can involve 5 fractions.Dosimetric impact of heterogeneity of chest
In addition to motion uncertainty, tissue density heteroge-
neity of chest organs can have a significant impact on
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greater physical distance in low-density tissues. The density
of lung parenchyma is only about one-third of that of solid
tissues such as the heart and major vessels. In addition, the
trachea and bronchus have airways. These unique com-
plexities of the chest organs can impose significant chal-
lenges for predicting accurate PBS-PT dose distribution
especially under the influence of organ or target motion. In
addition, dose calculation accuracy in heterogeneous tis-
sues may be a concern (11).Basic Requirements for Implementing PBS-PT
in Thoracic Cancers
To understand basic dosimetric properties under the influ-
ence of moving organs and targets, each institution should
perform basic measurements using a moving phantom that
can be as simple as slabs on the 1-dimensional moving
platform. Through measurements under different delivery
conditions, including but not limited to different target sizes
and locations, as well as the number of repainting of the
target, it is possible to establish a threshold of the motion
amplitude in which the interplay effect is small for various
scenarios. For example, Tsunashima (22) demonstrated that
the interplay effect was minimal for a motion amplitude
<5 mm for a particular set of beam properties. For thoracic
cancers treated with PBS, 4-dimensional (4D) CTebased
motion evaluation, management, planning, and delivery is
required as described in the following sections.Treatment Simulation, Contouring, and Target
Definition
All patients should undergo 4D CTebased treatment
simulation to determine the magnitude of tumor motion
(23). For patients who can be treated while “free breath-
ing,” an internal gross tumor volume (IGTV) should be
generated by using either a union of gross tumor volumes
(GTVs) on all respiratory phases or an outline of GTV on
the maximum intensity projection CT scan and verified
through different breathing phases. For patients to be
treated with breath hold (BH), multiple BH CT scans
should be acquired and the IGTV should be generated by
using a union of all GTVs defined on each different BH
scan. For patients to be treated with respiratory gating, the
IGTV should be defined based on the gating window. The
internal clinical target volume (ICTV) is defined as a 5- to
10-mm (or more for esophageal cancer) isotropic expansion
of the IGTV that is edited clinically based on the pattern of
tumor spread and anatomic boundaries (vertebral body,
chest wall, esophagus, heart, and great vessels, among
others). It should be pointed out that the ICTV defined here
is somewhat different from the internal target volume
defined by the International Commission on Radiation
Units & Measurements (24). The planning target volume(PTV), defined as an expansion of the ICTV, typically by
5 mm, should be used for reporting and evaluation purposes
(25). Strictly speaking, the PTV concept cannot be directly
used for PT planning because the range uncertainties are
beam direction specific. Beam-specific PTVs (26, 27) or
water-equivalent thickness (WET)einternal target volume
(28) could be used for single-field optimized (SFO) plans
(defined in Appendix E1; available online at www
.redjournal.org).
Treatment Planning
For free-breathing treatment, the averaged 4D CT set with
an IGTV density override (ie, using an average HU inside
the solid GTV [typically 40-60 HU]) (29) should be used to
create PBS plans. Two “verification” dose distributions,
created by recalculating the dose on the 4D CT scans at 2
extreme breathing phases (maximum inhale [T0] and
maximum exhale [T50]) with the original plan, should be
generated, and the original plan should be adjusted until the
verification and original dose distributions all meet the
required target coverage and normal tissue criteria. Simi-
larly, plans for patients undergoing BH and plans for pa-
tients undergoing gating should be developed on 1 BH scan
and 1 phase CT scan within the gating window, respec-
tively, if target motion is greater than each institutionally
established threshold value and validated on additional BH
CT scans (for BH patients) or phase CT scans (for gating
patients).
In general, if there is significant motion (eg, >5-10 mm),
an SFO technique is preferred to minimize motion uncer-
tainty particularly when 4D dose calculation and/or evalu-
ation and robust optimization tools are not available. An
SFO plan with multiple fields is effectively equivalent to
multiple volumetric rescannings (30). An MFO technique
should be used to treat patients with little target motion or
patients for whom proper motion mitigation strategies are
successfully applied. MFO plans usually produce more
conformal dose distributions than SFO plans; however, they
are more sensitive to target motion or variation of the
radiologic path length from each beam.
Motion Management Strategies
Personalized (patient-specific) motion analysis
The motion of thoracic tumors has been evaluated on 4D
CT images (31-34). Thoracic tumors do move, but most
have limited motion. For example, for locally advanced
NSCLC, only 35% to 39% of tumors move >0.5 cm and
only 5% of tumors move >1.3 cm in the superior-inferior
direction; on the other hand, among early-stage tumors,
about 50% move >0.5 cm and 5% move >2.0 cm in the
superior-inferior direction (31, 34). In a study involving
real-time measurement of implanted fiducial markers with
orthogonal fluoroscopic imaging, Seppenwoolde et al (35)
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in the superior-inferior direction, especially for unfixed
tumors in the lower lobe of the lung. In studies of tumor
motion for photon therapy, motion was normally charac-
terized in terms of the centroid movement of the GTV
(31, 32, 35, 36). For PT, one needs to know not only the
centroid movement but also changes in tissue density along
the entire proton beam path owing to respiration (usually
measured with the WET method, as described later). For
PBS-PT, the dosimetric impact of tumor motion is an even
more complex function involving intrafractional and
interfractional motion, the size of the target volume, the
treatment plan, and the delivery system, including the
scanning time, spot size, number of fields used, and number
of fractions, among other factors (15, 18-20).
Potential effects of intrafractional motion from respira-
tion on the treatment plan should be assessed by analyzing
the motion in directions both parallel and perpendicular to
the beam axis. The maximum inhale (T0) and maximum
exhale (T50) phases of 4D CT simulation images should be
mapped by using deformable image registration software
(37, 38). The deformation vectors of voxels contained in the
target volume should be used to calculate the distance
traveled by the tissue in the direction that is both perpen-
dicular (Mt) and parallel (Mjj) to the beam axis, as
described in detail in Appendix E2 (available online at
www.redjournal.org).
The analysis and recommendations described in
Appendix E2 (available online at www.redjournal.org) are
consistent with previous recommendations (30) to select
beam directions as parallel as possible to the main direction
of target motion. However, the greatest motion is often
along the superior-inferior direction (31, 34, 35), which is
not feasible for beam direction selection.
Consideration of proton beam path length, previous
irradiation (if applicable), patient anatomy, and the WET
and motion analyses should be used to select beam angles
for a given patient by use of an iterative process, while one
should keep in mind that the beam should not range into the
critical structures, especially those that could be affected by
motion interplay or anatomic changes. For patients previ-
ously treated with radiation therapy, consideration should
be given to choosing beam angles in which the dose passes
through the nonfunctional or fibrotic lung and limits the
dose to previously irradiated portions of the esophagus,
spinal cord, brachial plexus, heart, and skin to minimize the
risk of severe side effects.
Motion analysis tools such as the tool described here are
not currently commercially available.We strongly encourage
vendors of treatment planning systems to implement similar
tools as an integral part of these systems (39, 40).Four-dimensional dose and dynamic dose
The motion analysis described earlier is the first step to-
ward personalized motion management. It does not provideany quantitative information on the dosimetric impact of
motion. For example, for the same magnitude of motion,
the dosimetric effect is much larger for a smaller target
volume than for a larger volume because of interplay ef-
fects (19, 20). The concepts of 4D accumulated dose (4DD)
and 4D dynamic accumulated dose (4DDD) based on 4D
CT images should be used to estimate the dosimetric
impact. Unfortunately, 4DD and 4DDD are not available
for most commercial planning systems. Vendors of treat-
ment planning systems are strongly encouraged to imple-
ment 4DD and 4DDD as an integral part of their systems.
The 4DD is the averaged sumof the doses calculated on all
N (typically 10) individual phases of a 4D CT scan using the
planned fluence without considering the time dependence of
the delivery fluence. To calculate the 4DDD, details on the
time dependence of the delivery fluence are considered
together with changes in anatomy owing to respiratory mo-
tion (19, 20, 41). A detailed discussion of 4DD and 4DDD is
presented in Appendix E3 (available online at www
.redjournal.org). Assuming that the 4D CT scan is a true
representation of the patient’s anatomy, studies have shown
that the 4DDD converges to the 4DD, meaning that the
interplay effect can be averaged out because of its random
nature, after multiple fractions (41, 42). The recalculated
dose distributions on T0 and T50 represent the extremes of
systematic differences from the nominal dose distribution
(41, 43) and can be used to quantify the dose degradation
owing to respiratory motion.
One group has proposed using the difference between
single-fraction 4DD (1FX4DD) and single-fraction 4DDD
(1FX4DDD) to evaluate interplay effects on treatment plans
(20, 43). Figure 1 is an example of a clinical workflow based
on using the difference between 1FX4DD and 1FX4DDD to
evaluate the coverage of the target volume by the prescribed
dose. If the difference is less than the established criterion (in
this example, 3%), the patient could be treated with PBS-PT.
If the criterion cannot bemet, several techniques to effectively
reduce the interplay effect could be used during the planning
process, including selecting the scanning direction along the
largest component ofmotion (22, 44-46), smaller spot spacing
(47), optimized delivery sequence (48), layered rescanning
(20, 49, 50), or volumetric rescanning (27, 30, 49-51).
Notably, reducing spot spacing will increase treatment de-
livery time as well as increase the possibility of amonitor unit
(MU) “starvation” effect due tominimumMUper spot (52). If
the interplay effect must be reduced further, another option is
to use (1) 3D robust optimization (53) or 4D robust
optimization (43, 53); or (2) motion mitigation strategies, if
available, during treatment delivery, including rescanning
(either layered rescanning [20, 49, 50] or volumetric
rescanning [30, 49-51]), BH (54), gating (55, 56), and tracking
(57, 58). All of these strategies in the planning and delivery
processes could be used independently or in combination for
individual patients, but the selection is subject to which stra-
tegies are available at the treating institution. In any event, if
the dosimetric criteria are met, the patient can be treated with
PBS-PT; otherwise, PBS-PT should not be offered.
Fig. 1. Example of a clinical workflow based on using the difference between single-fraction 4-dimensional dynamic
accumulated dose (1FX4DDD) and single-fraction 4-dimensional accumulated dose (1FX4DD) to evaluate the target volume
to be covered by the prescribed dose, with various motion mitigation strategies to be used if needed. Abbreviations:
BH Z breath hold; CTV Z clinical target volume; 4DRO Z 4-dimensional robust optimization; IMPT Z intensity
modulated proton therapy; LRS Z layered rescanning; N Z no; ODS Z optimized delivery sequence; RO Z robust
optimization; SD Z scanning direction; Vp Z volume of CTV that receives at least prescribed dose; VRS Z volumetric
rescanning; Y Z yes.
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optimization
A robust evaluation method for PBS-PT based on worst-
case scenarios was first introduced by Lomax (11). This
worst-case robustness approach (Appendix E4; available
online at www.redjournal.org, for some details) has also
been implemented for 3D robust optimization (13, 59, 60).
A difference of less than some threshold value (most
commonly, 5%) between the worst-case dose distribution
and the nominal dose is considered acceptable. If the plan is
not robust (ie, it exceeds the threshold value), then the plan
should be reoptimized. Inoue et al (38) recently demon-
strated that 3D robustly optimized plans for stage III
NSCLC are only minimally affected by setup and range
uncertainties, breathing motion, and interplay effects.
The 3D robust optimization technique has been extended
to 4D robust optimization by incorporating the 4D CT
images from all breathing phases (43, 53, 61). In practice, it
may be sufficient to only include the maximum inhale (T0)
and maximum exhale (T50) of the 4D CT images in
addition to the planning CT dataset of the averaged 4D CT
images (43). Use of 4D robust optimization could effec-
tively reduce the sensitivity of the plan to interplay effects.Three-dimensional robust optimization has become
available in some commercial treatment planning systems,
but 4D robust optimization is still new and is not available
in most commercial planning systems at this time. For a
given patient motion, a 3D robustly optimized plan is less
sensitive to the interplay effect than a nonerobustly opti-
mized plan, and the 4D robustly optimized plan has the
least interplay effect (53).
Motion mitigation for treatment delivery
Some patient and treatment parameters can be modified to
minimize dose degradation caused by the interplay effect.
Using larger spot sizes, lengthening the effective delivery
time, and modifying the initial breathing phase when PT
commences have all been shown to result in improved dose
homogeneity in moving targets (15, 41, 48, 62-65).
Notably, spot size is often facility dependent, although
some institutions may have the same beam line with
different spot sizes or different beams with different spot
sizes (66). One of the practical methods of increasing spot
size is the use of a range shifter with a larger air gap (67).
More significantly, increasing the dose fractionation and
using multiple beam angles result in greater improvements
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the radiobiological effect with inhomogeneous fractionated
doses has yet to be determined. Moreover, normal varia-
tions in breathing periods may result in less sensitivity to
interplay effects (62). In addition to these factors, motion
mitigation techniques for more robust delivery for moving
targets have been or are being developed. The techniques
described in the following sections should also be consid-
ered when motion is beyond the acceptable threshold.
Rescanning
Rescanning, also known as repainting (44), is a simple
delivery-based technique used to minimize the dose un-
certainty caused by the interplay effect. Rescanning allows
dose inhomogeneities to be smoothed out or “smeared” by
visiting each pencil-beam spot position several times during
the delivery; however, it cannot reduce the dose blurring
caused by the interplay effect (30). Rescanning techniques
can be based on 2-dimensional (layered) or 3D (volumetric)
rescanning, each of which has its own advantages and
disadvantages (15, 20, 49-51, 68, 69). For layered rescan-
ning, so-called isolayered rescanning has shown to be more
practical and easier to implement (20, 49, 68). It involves
setting the maximum dose or maximum MU for each visit
of the spot locations. The maximum value per visit cannot
be smaller than the minimum MU per dose, set by the
hardware, which is machine dependent. Spots with weights
that exceed the maximum are revisited after the previous
scan until all rescanning is completed. The maximum dose
or MU per visit could be reduced by increasing the number
of rescannings, but this would also increase the treatment
delivery time. In layered rescanning, each energy layer is
completely rescanned before changing to the next energy
layer. Volumetric rescanning consists of repetitive scanning
through the whole target volume (49, 58) and thus requires
systems with fast energy switching (49, 68). Recent evi-
dence has suggested that volumetric scanning may suffer
from coherence effects between the applied scan period and
the period of motion, resulting in larger fluctuations in dose
homogeneity (50, 51, 68, 69). For systems with fast energy
switching times, both volumetric rescanning and layered
rescanning could be viable approaches to motion mitigation
(68). For systems with slower energy changes, layered
rescanning is optimal (50, 68). Layered rescanning is
currently in clinical use for some patients at several in-
stitutions. However, some delivery systems have inherent or
mandatory rescanning requirements owing to system-
specific parameters, and machine specifications may
impose limitations on the implementation of any given
rescanning strategy, whether layered or volumetric (51).
Therefore, the effectiveness of rescanning should be eval-
uated on a facility-specific and patient-specific basis.
When an SFO technique is used, the number of fields
used is equivalent to the number of volumetric rescannings,
because each SFO field delivers a fraction of the prescribed
dose to the entire target volume proportional to the field
weight. Fractionated treatment can also provide effectiverescanning (15, 19, 20, 41, 42). For hypofractionation
treatments, rescanning should be mandated, either volu-
metric or layered, to reduce the uncertainty.
BH, gating, and tracking
BH, gating, and tracking are motion mitigation techniques
that could minimize the effect of respiratory motion during
delivery, thereby reducing potential underdosing of the target
volume or excessive dose to healthy tissues for moving tu-
mors (50). These techniques can be used in combination with
layered or volumetric rescanning (50, 69). Notably, in-room
volumetric imaging, such as CT on rails or cone beam CT
(CBCT), is necessary for consistency in BH or gating level
through monitoring the breathing baseline (fortunately, in-
room volumetric imaging has become standard in new par-
ticle therapy facilities). For treatment delivery systems in
which in-room volumetric imaging is not available, the use of
implanted fiducial markers with fluoroscopic imaging could
be an effective gating surrogate.
For BH treatment delivery, the radiation is delivered
only when the patient is holding his or her breath to a
certain level, and the beam is otherwise on hold. Active
respiratory control and deep-inhalation BHs are already
well-established motion mitigation strategies for photon
delivery (70). For PBS-PT, a recent simulation study
demonstrated that BH is a realistic clinical approach for
treating thoracic tumors. However, large baseline shifts and
small target volumes with substantial motion are potential
concerns for BH treatment delivery (54), along with the
ability of a patient to undergo BH in a consistent manner.
Gated treatment, on the other hand, involves radiation
delivery that is synchronized with a gating signal and
triggered only within a preset gating window. The gating
signal can come from within the patient (eg, fiducials) or
outside the patient (eg, via a real-time positioning man-
agement system). The correlation between gating signals
and motion of the target volume should be established for
each patient and monitored closely during each treatment
session. The gating window is usually set at a certain per-
centage level of the averaged respiratory amplitude (ie,
phase based). However, a fundamental assumption in gated
treatment is that the respiratory signal correlates well with
the actual tumor motion, which may not be the case for all
patients. In addition, the primary tumor may move on a
different trajectory from the nodes.
Currently, only a few centers are using gating systems
for PBS-PT; one such system is in use at Hokkaido Uni-
versity (55, 71, 72). This “real-time imaging and gating
system” involves implantation of gold fiducial markers near
the tumor, which is used to identify marker positions
relative to the tumor core. A 2-directional x-ray fluoroscopy
system is then used to automatically pinpoint the marker
positions on fluoroscopic images by pattern recognition,
and those spatial positions are repeatedly calculated at
regular intervals from 1 to 30 Hz. The treatment beam ir-
radiates the targeted tumor only when the gold markers are
within a few millimeters of the planned positions. The
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irradiation of moving tumors. Compared with conventional
methods that irradiate the entire area in which the tumor
might migrate, this system can reduce the irradiated volume
by 50% to 75%, which can represent a significant reduction
in the irradiation of normal tissue (55, 56, 72, 73).
Combining gating and rescanning, the National Institute of
Radiological Sciences in Japan has implemented phase-
controlled rescanning for its carbon ion system (74).
Tracking for particle therapy involves lateral adaptation
of pencil-beam position and energy changes to modify the
longitudinal position of the Bragg peak (58, 75). It also
requires one to have a real-time 3D model of the patient to
adapt for WET changes in the beam path. The concept of
tracking was initially proposed for photon therapy with the
use of multileaf collimators (76). Tracking for particle
therapy is probably the most precise motion mitigation
strategy, but it is technically challenging and is not avail-
able for clinical use at this time (39, 40, 58, 75, 77).Quality Assurance and Adaptive Planning
Patient-specific quality assurance for PBS-PT, especially
IMPT, is challenging because of the complex dose distribu-
tions of the treatment fields. Currently, measurements are
made with a 2-dimensional ion chamber array detector for
PBS treatment fields (78-80), and 3D detectors are being
developed (81-84). To treat moving targets with a PBS
technique, motion interplay effects and the effectiveness of
motion mitigation strategies should be evaluated before pa-
tient treatment. A 4Dphantom is recommended to be used for
this purpose, as demonstrated in the literature (39, 40, 75).
However, the challenge is the lack of any commercially
available standardized 4D phantoms.
All patients should undergo repeat 4D CT verification
simulations to determine whether adaptive replanning is
needed to maintain target coverage (eg,>95% for the ICTV)
and to avoid overdosing critical structures (4, 85). In the future,
4D magnetic resonance imaging could play an increasingly
important role for motion verification with superior soft tissue
contrast and no imaging dose (86, 87). Studies have suggested
that even with robust optimization, about 30% of IMPT pa-
tients still require adaptive planning, mainly because of
anatomy change over the course of the treatment (16, 88). In-
room volumetric imaging techniques such as CBCT and in-
room CT could also be used to identify possible anatomy
changes. However, dose calculation on CBCT may not be
sufficiently accurate, and 4D imaging also may not be avail-
able with these techniques. Therefore, verification 4D CT
simulation for PBS-PT patients should be performed more
frequently, such as on a weekly basis. The plan should be
recalculated on the repeat 4D CT scans. Contours should be
deformed from the planning CT scan to the verification CT
scan, and the treating physician should review the new con-
tours and dose-volume histograms. If an adaptive plan is
deemed necessary, then it should be developed by usingtechniques as described earlier, and the same patient-specific
quality assurance process should be repeated before treat-
ment with the adapted plan. Interfractional changes in anat-
omy and motion patterns arising from tumor shrinkage or
patient weight loss or gain further require systematic moni-
toring and timely adjustment of treatment plans over time
(25). Adaptive PT has the ability to correct for dosimetric
effects induced by interfractional anatomic changes and it
complements the ability of image guided setup to correct for
setup uncertainty.
Summary
We recommend the following strategies to successfully
implement PBS-PT including IMPT for thoracic malig-
nancies in clinical settings:
1. Perform basic measurements using a moving phantom to
establish a threshold of the motion amplitude where the
interplay effect is small.
2. Evaluate tumor motion using 4D CTebased evaluation
and/or management to allow better selection of beam
angles (as shown in Fig. E1; available online at www
.redjournal.org).
3. Perform motion analysis. Compare 1FX4DDD and
1FX4DD to determine whether motion mitigation is
necessary or sufficient.
4. Use dose distributions calculated on T0 and T50 to
quantify the extremes of systematic dose degradation due
to respiratory motion.
5. Use rescanning (either layered or volumetric) to reduce
interplay effects, bearing in mind that use of SFO plans
with multiple fields is effectively equivalent to volu-
metric rescanning and fractionated treatment delivery
also provides effective rescanning. Use BH or gating as
needed based on motion evaluation or a combination of
any of these techniques with rescanning.
6. Use an optimized delivery sequence, including scanning
direction, to minimize interplay effects.
7. Use 3D robust optimization to minimize the impact of
organ motion. Use 4D robust optimization to further
improve the robustness to intrafractional motion for large
organ motion or in short fractionation schemes.
8. Perform verification 4D CT more frequently, such as on a
weekly basis, to determine whether adaptive replanning
is needed to maintain plan robustness.
Current challenges to implementing these recommen-
dations are as follows:
1. Software tools for tumor motion analysis are not
commercially available.
2. Commercial treatment planning systems do not calculate
dynamic doses.
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are not commercially available on many systems.
4. Rescanning and gating may not be available in some
proton treatment delivery systems.
5. The capability to perform in-room volumetric imaging
(CBCT, CT) has only recently become available at some
institutions.
6. No standardized 4D phantom is commercially available
for evaluation or accreditation.
We strongly encourage vendors to implement motion
analysis tools, dynamic dose calculation, 4D robust opti-
mization, rescanning, optimized delivery sequencing,
gating, and diagnostic quality volumetric imaging and to
commercialize a standard 4D phantom as quickly as
possible. We recommend that each institution establish its
acceptable tumor motion criteria based on its motion
management strategy. If the extent of target motion is
greater than the institutional criteria, then motion mitiga-
tion strategies such as rescanning, BH, or respiratory gating
should be strongly considered. The availability of patient-
specific, tumor motionerelated dose uncertainty analysis
and 3D and 4D robust optimization, as well as the avail-
ability of adaptive replanning to account for potential mo-
tion and anatomic changes during the course of radiation
therapy, would further enhance the institution’s ability to
select proper patients. Each institution should follow the
guidelines proposed here and optimize its motion man-
agement, planning, and delivery of PBS-PT using available
tools and techniques. A learning curve is expected, and
SFO plans should be considered first at the beginning of
implementing PBS-PT to reduce motion uncertainty. If
basic requirements cannot be met, patients should not be
treated with PBS-PT. Enrollment in a clinical trial is
strongly recommended.References
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